Pathos develops an AI-enabled drug discovery platform to reduce the medication development process. Its self-learning pl
Pathos develops an AI-enabled drug discovery platform to reduce the medication development process. Its self-learning platform utilizes big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy.
Discovery Tools (Healthcare)📍 Chicago, IL
Current Valuation
$600M
as of 2024-Q4
PRIVATE
QL Price
$600M
0% vs last round
QuantLogix's current estimate for Pathos, published 2026-09-27 — in line with the last disclosed round of $600M (2024-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$600M
2024-Q4
weight 0.3
How this price has held up
No round has priced for Pathos since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Pathos, 2026-09-27 (b82204256de69456).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Pathos going public?
No. Pathos is private and has not filed to go public. There is no S-1 on file.
What is Pathos' valuation in 2026?
Pathos is valued at $600M as of 2024-Q4, set by its Series C ($62M, Oct 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Pathos filed an S-1?
No public S-1 is on file for Pathos.
How much has Pathos raised?
Pathos has raised $102M in total, most recently a Series C of $62M in Oct 2024.
Is Pathos publicly traded — can you buy Pathos stock?
No. Pathos is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Pathos on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Name-verified against lead sponsor "Pathos AI, Inc." on ClinicalTrials.gov as of 2026-09-20. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▼ Hiring downtrend
-40% vs 2026-08
Open roles
3
via ashby
Product-build share
33%
engineering, research, product, design
Trajectory
tightening
balanced build + GTM — 33% builders vs 67% go-to-market/G&A — scaling both sides.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
AI Research EngineerFounding Marketing LeadFounding Sales Lead (Enterprise)
Counted from Pathos's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q4. Refreshed quarterly.